By Padmanabhan Ananthan and Christy Santhosh (Reuters) -The U.S. Food and Drug Administration approved Arrowhead Pharmaceuticals’ drug for a type of genetic disorder that causes extremely high levels of fat in the bloodstream, the company said on Tuesday, sending its shares up more than 4%. The approval marks Arrowhead’s first product on the market and […]
Health
US FDA approves Arrowhead’s genetic disorder drug
Audio By Carbonatix
By Padmanabhan Ananthan and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration approved Arrowhead Pharmaceuticals’ drug for a type of genetic disorder that causes extremely high levels of fat in the bloodstream, the company said on Tuesday, sending its shares up more than 4%.
The approval marks Arrowhead’s first product on the market and the second U.S.-authorized treatment for a hereditary condition known as familial chylomicronemia syndrome.
The annual wholesale cost of the drug, branded as Redemplo, is $60,000, CEO Christopher Anzalone told analysts in a conference call.
The drug will be available in the U.S. before the end of the year.
FCS is a rare inherited disorder caused by defects in lipoprotein lipase, an enzyme responsible for breaking down fat particles, leading to very high triglyceride levels in the blood.
The disorder causes symptoms such as abdominal pain and, in severe cases, acute pancreatitis.
Ionis Pharmaceuticals’ monthly injectable drug Tryngolza is also approved to treat the condition. It was launched in December 2024 and brought in $32 million in the third quarter of 2025.
Redemplo, with injections once every three months, provides a more convenient dosing schedule, Anzalone told Reuters before approval.
The drug uses RNA-based technology to reduce the production of apolipoprotein C-III, a protein that helps regulate fat metabolism.
“We think Arrowhead’s drug will capture a larger market share,” B. Riley Securities analyst Madison El-Saadi said ahead of the decision, adding Redemplo has a better profile compared to Ionis’ Tryngolza.
Analysts on average expect the drug to bring about $1.4 billion by 2031, according to data compiled by LSEG.
In a late-stage study with 75 patients, Redemplo reduced triglycerides, a key hallmark of the disease, by 80% and cut the risk of pancreatitis by 83% versus placebo.
Arrowhead has partnered with Sanofi for Redemplo, giving the French drugmaker exclusive rights to develop and commercialize the drug in Greater China.
(Reporting by Padmanabhan Ananthan and Christy Santhosh in Bengaluru; Editing by Tasim Zahid and Vijay Kishore)